MIDATECH PHARMA PLC-ADR (MTP) Fundamental Analysis & Valuation

NASDAQ:MTP • US59564R5000

Current stock price

0.2851 USD
-0.06 (-18.52%)
At close:
0.2801 USD
-0.01 (-1.75%)
After Hours:

This MTP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MTP Profitability Analysis

1.1 Basic Checks

  • In the past year MTP has reported negative net income.
  • In the past year MTP has reported a negative cash flow from operations.
MTP Yearly Net Income VS EBIT VS OCF VS FCFMTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -5M -10M -15M -20M

1.2 Ratios

  • The profitability ratios for MTP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTP Yearly ROA, ROE, ROICMTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTP Yearly Profit, Operating, Gross MarginsMTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MTP Health Analysis

2.1 Basic Checks

  • MTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MTP has been increased compared to 1 year ago.
  • Compared to 1 year ago, MTP has a worse debt to assets ratio.
MTP Yearly Shares OutstandingMTP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2M 4M 6M
MTP Yearly Total Debt VS Total AssetsMTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

2.2 Solvency

  • MTP has an Altman-Z score of -12.33. This is a bad value and indicates that MTP is not financially healthy and even has some risk of bankruptcy.
  • MTP has a Altman-Z score of -12.33. This is amonst the worse of the industry: MTP underperforms 81.14% of its industry peers.
  • MTP has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • MTP has a worse Debt to Equity ratio (0.07) than 62.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -12.33
ROIC/WACCN/A
WACC6.79%
MTP Yearly LT Debt VS Equity VS FCFMTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M 40M

2.3 Liquidity

  • MTP has a Current Ratio of 5.28. This indicates that MTP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.28, MTP is in line with its industry, outperforming 47.70% of the companies in the same industry.
  • A Quick Ratio of 5.28 indicates that MTP has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.28, MTP perfoms like the industry average, outperforming 48.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28
MTP Yearly Current Assets VS Current LiabilitesMTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MTP Growth Analysis

3.1 Past

  • MTP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.43%, which is quite impressive.
  • MTP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.98%.
  • The Revenue for MTP have been decreasing by -15.26% on average. This is quite bad
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTP Yearly Revenue VS EstimatesMTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M
MTP Yearly EPS VS EstimatesMTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. MTP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MTP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTP Price Earnings VS Forward Price EarningsMTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTP Per share dataMTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MTP Dividend Analysis

5.1 Amount

  • MTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MTP Fundamentals: All Metrics, Ratios and Statistics

MIDATECH PHARMA PLC-ADR

NASDAQ:MTP (3/24/2023, 8:00:00 PM)

After market: 0.2801 -0.01 (-1.75%)

0.2851

-0.06 (-18.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)04-24
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.98M
Revenue(TTM)645.00K
Net Income(TTM)-5.37M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.12
BVpS1.34
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z -12.33
F-Score2
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)40.47%
Cap/Depr(5y)39.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.58%
OCF growth 3YN/A
OCF growth 5YN/A

MIDATECH PHARMA PLC-ADR / MTP Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MIDATECH PHARMA PLC-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to MTP.


Can you provide the valuation status for MIDATECH PHARMA PLC-ADR?

ChartMill assigns a valuation rating of 3 / 10 to MIDATECH PHARMA PLC-ADR (MTP). This can be considered as Overvalued.


Can you provide the profitability details for MIDATECH PHARMA PLC-ADR?

MIDATECH PHARMA PLC-ADR (MTP) has a profitability rating of 0 / 10.